home / stock / atos / atos quote
Last: | $1.80 |
---|---|
Change Percent: | -1.09% |
Open: | $1.85 |
Close: | $1.80 |
High: | $1.91 |
Low: | $1.755 |
Volume: | 1,873,373 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.8 | $1.85 | $1.8 | $1.91 | $1.755 | 1,873,373 | 03-28-2024 |
$1.83 | $1.82 | $1.83 | $1.87 | $1.7 | 2,548,777 | 03-27-2024 |
$1.8 | $1.92 | $1.8 | $1.94 | $1.72 | 3,789,850 | 03-26-2024 |
$1.89 | $1.65 | $1.89 | $1.89 | $1.61 | 3,230,483 | 03-25-2024 |
$1.67 | $1.7 | $1.67 | $1.7 | $1.57 | 1,869,631 | 03-22-2024 |
$1.68 | $1.65 | $1.68 | $1.7 | $1.57 | 2,556,091 | 03-21-2024 |
$1.63 | $1.62 | $1.63 | $1.73 | $1.53 | 6,819,228 | 03-20-2024 |
$1.55 | $1.31 | $1.55 | $1.57 | $1.2873 | 4,693,064 | 03-19-2024 |
$1.29 | $1.29 | $1.29 | $1.3399 | $1.24 | 818,032 | 03-18-2024 |
$1.29 | $1.17 | $1.29 | $1.295 | $1.1501 | 1,202,447 | 03-15-2024 |
$1.2 | $1.26 | $1.2 | $1.27 | $1.1 | 777,806 | 03-14-2024 |
$1.26 | $1.32 | $1.26 | $1.32 | $1.12 | 1,507,236 | 03-13-2024 |
$1.31 | $1.23 | $1.31 | $1.33 | $1.21 | 2,328,805 | 03-12-2024 |
$1.2 | $1.12 | $1.2 | $1.25 | $1.1 | 1,490,436 | 03-11-2024 |
$1.09 | $1.1 | $1.09 | $1.17 | $1.08 | 1,140,413 | 03-08-2024 |
$1.1 | $1.19 | $1.1 | $1.25 | $1.08 | 1,665,217 | 03-07-2024 |
$1.15 | $1.04 | $1.15 | $1.2 | $1.02 | 2,918,223 | 03-06-2024 |
$1.02 | $1.01 | $1.02 | $1.03 | $0.9901 | 305,039 | 03-05-2024 |
$1.02 | $0.9904 | $1.02 | $1.04 | $0.9901 | 512,160 | 03-04-2024 |
$1 | $0.982 | $1 | $1.02 | $0.98 | 336,575 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-), breast cancer patien...
SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceuti...